|
05-21-2012, 08:01 AM
|
#1
|
Senior Member
Join Date: Feb 2010
Location: TN
Posts: 175
|
Her2 extracelluar domain test
Does anyone know what the "serum HER2 extracellular domain (ECD) level" test is? I am assuming that it is not the same as the FISH or IHC tests that were done when we were first diagnosed with Her2+ breast cancer. I wonder if this test might become routine on new breast cancer cases, if as this abstract suggests it is a way to see how successful Herceptin might be.---bird
Anticancer Res. 2012 Apr;32(4):1429-33.
Elevated HER2 extracellular domain level in primary breast cancer with HER2 overexpression predicts early failure of adjuvant trastuzumab.
Thureau S, Clatot F, Laberge-Le-Couteulx S, Baron M, Basuyau JP, Blot E.
Source
Department of Radiotherapy, Henri Becquerel Center, Rouen, France. sebastien.thureau@chb.unicancer.fr
Abstract
AIM:
To investigate in a prospective study the prognostic value of serum HER2 extracellular domain (ECD) level in patients with primary breast cancer overexpressing HER2 treated with adjuvant chemotherapy and trastuzumab.
PATIENTS AND METHODS:
All the patients treated for primary breast cancer with chemotherapy and adjuvant trastuzumab from April 1, 2005 to December 31, 2006 at the Centre de Lutte Contre le Cancer de Haute Normandie were enrolled in this prospective study. HER2 ECD was measured in frozen serum by a commercial kit with a cut-off value of 15 ng/ml.
RESULTS:
Sixty-five patients were enrolled. Seven patients (11%) had an elevated serum HER2 ECD level (mean=25.1 ng/ml, range 15.1-38.9 ng/ml). During follow-up, 13 patients (20%) developed metastases and seven patients (11%) died. Death was related to breast cancer metastases in six patients (9%). Out of the seven patient with elevated serum HER2 ECD level, five (71%) developed metastases and three (43%) died of metastases during follow-up. Multivariate analysis showed that elevated serum HER2 ECD level was the unique factor for both disease-free survival (p<0.0006) and overall survival (p=0.008) in this series.
CONCLUSION:
Elevated serum HER2 ECD level is a strong prognostic factor in primary breast cancer overexpressing HER2 treated with adjuvant therapy of trastuzumab. In addition, our results suggest that it could predict failure of adjuvant therapy of trastuzumab.
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|
|
|
05-21-2012, 08:09 AM
|
#2
|
Senior Member
Join Date: Oct 2005
Location: Lakeville, Minnesota
Posts: 199
|
Re: Her2 extracelluar domain test
I have the her2 serum test done, and we see it as a tumor marker, similar to the ca 27/29, etc.
I think the reliability is also similar to other tumor markers. For some, very reliable, but for others, not so much.
That being said, mine was at 14.9 the first time I had it tested and now is done to 12, so I am happy.
Laurie
__________________
diagnosed stage 2- 3/2005
4.5 cm & 2+ nodes , er/pr- & HER2+
4 AC
12 taxol/Herceptin
Year of Herceptin
liver mets- July-2010
7 taxotere/Herceptin
RFA- Feb.2011
NED
U of Wa vaccine trial-oct 2011-Feb 2012
Herceptin/tykerb
Ned - 2 1/2 years
Herceptin & perjeta
Ned 3 years
Herceptin- reducing treatments , due to s/e, to 5-6 a year
NED- 3 1/2 years
Ned - 4 years
2/15- stopped herceptin - on no treatment
|
|
|
05-21-2012, 11:58 AM
|
#4
|
Senior Member
Join Date: Sep 2005
Location: Stockton, NJ
Posts: 4,179
|
Re: Her2 extracelluar domain test
I think it has to do with the fact if your Her2+ BC has receptors (regular nice long ones that would be bound by Herceptin) or if you are the rare bird (yes - pun intended ) that has the truncated receptors (tiny mis-formed ones) that cannot be bound by Herceptin.
Obviously, if you have the tiny mis-formed receptors, Herceptin cannot bind to them and work.
__________________
Kind regards
Becky
Found lump via BSE
Diagnosed 8/04 at age 45
1.9cm tumor, ER+PR-, Her2 3+(rt side)
2 micromets to sentinel node
Stage 2A
left 3mm DCIS - low grade ER+PR+Her2 neg
lumpectomies 9/7/04
4DD AC followed by 4 DD taxol
Used Leukine instead of Neulasta
35 rads on right side only
4/05 started Tamoxifen
Started Herceptin 4 months after last Taxol due to
trial results and 2005 ASCO meeting & recommendations
Oophorectomy 8/05
Started Arimidex 9/05
Finished Herceptin (16 months) 9/06
Arimidex Only
Prolia every 6 months for osteopenia
NED 18 years!
Said Christopher Robin to Pooh: "You must remember this: You're braver than you believe and stronger than you seem and smarter than you think"
|
|
|
05-21-2012, 02:36 PM
|
#5
|
Senior Member
Join Date: Feb 2010
Location: TN
Posts: 175
|
Re: Her2 extracelluar domain test
Yes, my doctor mentioned to me once about the possiblity of those truncated Her2 receptors being present. But he went on to say that Herceptin was really the only good choice I had, so truncated or not the Herceptin was applied. He's a pretty smart guy and I suspect if he felt the ECD test would have shed useful information on the efficacy of Herceptin in my case, he probably would have done it. Anyway, in this rare bird's case (I liked the pun Becky, btw) the 3 year cancerversary just passed and things are still looking good. So maybe those receptors I had were the good ones capable of easily catching Herceptin molecules....Thanks for all those links, Rich.--bird
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT -7. The time now is 07:57 AM.
|